04:14 PM EDT, 05/13/2024 (MT Newswires) -- Allogene Therapeutics ( ALLO ) reported Q1 net loss Monday of $0.38 per diluted share, narrowing from $0.69 a year ago.

Analysts polled by Capital IQ expected a loss of $0.41.

Collaboration revenue for the quarter ended March 31 was $22,000, down from $30,000 a year earlier. Analysts surveyed by Capital IQ expected $10,000.

The clinical-stage drugmaker said its cash, cash equivalents and investments were $397.3 million and it continues to expect its cash runway to fund operations into 2026.

The company shares were up 2% in recent after-hours activity.

Price: 2.9500, Change: +0.05, Percent Change: +1.72